SAJE Pharma’s small molecule platform regulates cellular nitrosylation, which provides 53 therapeutic benefits for multiple diseases with complex pathophysiological drivers, and all without any safety issues identified. Safely regulating so many disease drivers should be much more successful at benefitting complex diseases than regulating only one driver. 24 animal disease models and two human diseases have been therapeutically benefited by our technology which inhibits the enzyme, S-nitrosoglutathione reductase, GSNOR. Our lead molecule, SPL-850, is a composition of matter compound that we invented and own all rights to. It inhibits oxidative stress, inflammation, mitochondrial dysfunction, vascular dysfunction, fibrosis, BBB breakdown, protein and platelet aggregation. It prevents neurodegeneration in the brain, so is an ideal candidate for Pain, Alzheimer’s, Parkinson’s, MS, and TBI. CVD, autoimmune, ocular, & others are clinical targets. SAJE seeks partners for the clinic.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):